Global Erythropoietin Stimulating Agents Market Segmented by Type, Application, and Geography - Analysis, Growth, Trends & Forecast (2018 - 2023) - ResearchAndMarkets.com

DUBLIN--()--The "Global Erythropoietin Stimulating Agents Market - Segmented by Type, Application, and Geography - Growth, Trends, and Forecast (2018 - 2023)" report has been added to ResearchAndMarkets.com's offering.

The global erythropoietin stimulating agents market is estimated to grow at a CAGR of about 8.3% during the forecast period.

Erythropoietin stimulating agents are the drugs which are similar to erythropoietin. This agent stimulates the growth of red blood cells (RBC). Erythropoietin-stimulating agents are approved for the treatment of anemia due to chronic kidney failure (CKD), chemotherapy, HIV, and also for the reduced RBC during critical surgical procedures.

Over the past decade, anemia has emerged as one of the serious diseases related to nutrition, accompanied by increased morbidity and mortality. In major developing countries, neonatal and maternal mortality accounted for 3.0 million deaths, in 2013, and are important contributors to global mortality. Furthermore, about 90,000 deaths have been estimated in all genders and age groups, due to iron anemic deficiency. In 2013, WHO estimated that pregnant women (38%), non-pregnant women (29%), children (43%), and women of reproductive age (29%) suffer from anemia, corresponding to 496 million non-pregnant women, 273 million children and 32 million pregnant women, across the world. And even the chronic infections, including tuberculosis, malaria, HIV, and cancer can also lower blood Hb concentrations.

Asia-Pacific region is expected to grow at the highest CAGR, during the forecast period. Because of the emerging economies and new product launches with better efficacy, it will be a big opportunity for the erythropoietin stimulating agents market. North America region holds the largest market share, followed by Europe, in the forecast period.

Companies Mentioned

  • 3SBIO Inc.
  • Amgen
  • Hoffmann La Roche
  • Johnson & Johnson
  • Biosidus
  • Biocon
  • Hospira
  • Intas Pharmaceuticals
  • Celltrion
  • Teva Pharmaceuticals Industries.

Key Topics Covered:

1. Introduction

2. Research Methodology

3. Executive Summary

4. Key Inferences

5. Market Overview

6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)

7. Market Segmentation

8. Competitive Landscape

9. Key Players

10. Future of the Market

For more information about this report visit https://www.researchandmarkets.com/research/cdkh7h/global?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Liver and Kidney Disorders Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Liver and Kidney Disorders Drugs